Higher MACE, Cancer Risks With Tofacitinib-Treated RA Versus TNF Inhibitors
|
|
Tofacitinib might be effective in treating rheumatoid arthritis (RA), but a new study published in The New England Journal of Medicine raises the possibility that the downsides are too high. Researchers determined that tofacitinib-treated patients had a higher risk of major adverse cardiovascular events (MACEs) and cancer than patients treated with tumor necrosis factor (TNF) Inhibitors. Read more.
|